Lung Cancer (NSCLC), ROS1 (6q22) Rearrangement, FISH
Also known as: Crizotinib, FISH, Lung Cancer (NSCLC), Non-Small Cell Lung Cancer (NSCLC), Xalkori®
Use
Detects rearrangements of the ROS1 receptor tyrosine kinase gene at chromosomal region 6q22 in non‑small cell lung cancer (NSCLC), a critical biomarker associated with responsiveness to ROS1‑targeted tyrosine kinase inhibitors (e.g., crizotinib). Positive detections inform targeted therapy decisions in patients with advanced or metastatic NSCLC.
Special Instructions
Not provided.
Limitations
Detects ROS1 gene rearrangements via FISH but does not identify the specific fusion partner. Requires sufficient tumor tissue; decalcified or poor‑quality specimens may result in test failure.
New York Approved
Methodology
Chromosomal / Cytogenetics
Biomarkers
LOINC Codes
- 81747-8
Result Turnaround Time
7-10 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Send a lung tissue biopsy, formalin-fixed (6‑48 hours fixation recommended) paraffin block. Pathology report must accompany sample. Alternate specimen: 5×5 mm tumor tissue in culture transport medium or five 5‑micron (minimum 4 µm) sections on charged slides.
Storage Instructions
Room temperature
Causes for Rejection
Unstained slides not verified for tumor, fixatives other than formalin.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Indefinitely |
Other tests from different labs that may be relevant